Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Increase in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the target of a significant increase in short interest in April. As of April 30th, there was short interest totaling 125,511 shares, an increase of 169.5% from the April 15th total of 46,578 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily volume of 131,384 shares, the short-interest ratio is presently 1.0 days.

Dogwood Therapeutics Price Performance

Shares of DWTX stock opened at $1.98 on Friday. The stock has a market cap of $66.13 million, a P/E ratio of -0.10 and a beta of 1.68. The company has a fifty day moving average price of $2.12 and a two-hundred day moving average price of $3.65. Dogwood Therapeutics has a one year low of $1.28 and a one year high of $9.50.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. As a group, equities research analysts anticipate that Dogwood Therapeutics will post -0.93 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on DWTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a research report on Monday, April 27th. Weiss Ratings downgraded shares of Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Dogwood Therapeutics has a consensus rating of “Hold” and an average target price of $12.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP bought a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics at the end of the most recent quarter. Institutional investors own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.